Martin Ingelsson

Has grant

Specialist

Uppsala University Hospital
Country flagSweden

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Development of biomarkers for Parkinson´s disease and other neurodegenerative disorders with Lewy body pathology

Open Date: 2014-01-01

Close Date: 2015-01-01

Grant: Close

Investigation on the propagation and aggregation of alpha-synuclein - implications for future immunotherapy in Lewy body disorders

Open Date: 2014-01-01

Close Date: 2015-01-01

Grant: Close

Alpha-synuclein oligomers as a novel target for therapy and diagnostics in Parkinson’s disease and related disorders

Open Date: 2014-01-01

Close Date: 2015-01-01

Grant: Close

Alfa-synuklein - ny målmolekyl för framtida behandling av Parkinsons sjukdom

Open Date: 2014-01-01

Close Date: 2015-01-01

Grant: Close

Utveckling av monoklonala antikroppar mot alfa-synuklein protofibriller - nya möjligheter till diagnostik och behandling av Parkinsons sjukdom och relaterade tillstånd

Open Date: 2012-01-01

Close Date: 2015-01-01

Articles (12)

Year:

2026

Body mass index (BMI), type 2 diabetes (T2D) and associated cardiometabolic features modify Alzheimer’s disease (AD) risk, yet shared mechanisms remain poorly understood. Using sex- and age-stratified genotyping data for BMI and T2D, we investigate how these traits converge on shared genetic pathways to AD risk. Employing multi-trait, machine learning and single-cell transcriptomics, we identify sex-specific cardiometabolic liability linked to higher BMI-associated risk in women and T2D-driven risk in men. Variant-level analyses reveal AD risk associates with genetically-driven hypotension and hypoglycaemia. We identify 35 putative effector genes in seven independent loci colocalizing between BMI/T2D and AD, mapping to peripheral immune and metabolic tissues and cell-types. Pathway enrichment identifies druggable targets in calcium and potassium channel signaling. Across 81 approved drugs modulating shared risk genes, levosimendan - a calcium sensitizer for heart failure - inhibits tau oligomerization and emerges as a repurposing candidate. These findings elucidate sex-specific cardiometabolic drivers of AD, identify actionable biological pathways, and reveal drug candidates for AD prevention and treatment.

Year:

2026

Year:

2025

Background Plasma phosphorylated tau 217 (p-tau 217 ) is a robust biomarker of Alzheimer's disease (AD) pathology. However, its full potential as a dynamic marker has still not been verified in very old persons, i.e., those with the highest incidence of AD. Objective To examine the cross-sectional and longitudinal associations between plasma p-tau 217 concentration and cerebrospinal fluid (CSF) AD biomarkers. Further, to investigate the performance of p-tau 217 as a predictor of amyloid status in a cohort of very old men. Methods CSF AD biomarkers were analyzed in thirty-five 89-year-old men. Amyloid-β (Aβ) positivity was defined according to CSF Aβ 42 level. Plasma p-tau 217 concentration was measured at the mean age of 82, 87, and 91. Incident dementia diagnoses in survivors were identified through medical records up to the age of 102. Results Plasma p-tau 217 strongly correlated with CSF Aβ 42 concentration in Aβ-positive (n = 16, Spearman ρ : rho = −0.63, p = 0.009) but not in Aβ-negative (n = 19, rho = 0.111, p = 0.652) men and predicted Aβ status (area under the curve, AUC 0.91). Plasma p-tau 217 increased over ten years in the Aβ-positive group, while it remained unchanged in the negative group (p = 0.018). Conclusions Our findings indicate that plasma p-tau 217 is a predictor of brain Aβ deposition also in very old individuals.

Year:

2025

Year:

2025

Year:

2025

Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.

Year:

2025

Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.

Year:

2025

Neuroinflammation, particularly that involving reactive microglia, the brain’s resident immune cells, is implicated in the pathogenesis of major neurodegenerative diseases. However, early markers of this process are in high demand. Multiple studies have reported changes in ribosomal protein (RP) expression during neurodegeneration, but the significance of these changes remains unclear. Ribosomes are evolutionarily conserved protein synthesizing machines, and although commonly viewed as invariant, accumulating evidence suggest functional ribosome specialization through variation in their protein composition. By analyzing cell type-specific translating mRNAs from mouse brains, we identify distinct RP expression patterns between neurons, astrocytes, and microglia, including neuron-specific RPs, Rpl13a and Rps10 . We also observed complex expression relationships between RP paralogs and their canonical counterparts, suggesting regulated mechanisms for generating heterogeneous ribosomes. Analysis across brain regions revealed that Rplp0 and Rpl13a , commonly used normalization references, show heterogeneous expression, raising important methodological considerations for gene expression studies. Importantly, we show that Rps24 , an essential ribosome component that undergoes alternative splicing to produce protein variants with different C-termini, exhibits striking cell type-specific isoform expression in brain. The Rps24c isoform is predominantly expressed in microglia and is increased by neuroinflammation caused by aging, neurodegeneration, or inflammatory chemicals. We verify increased expression of S24-PKE, the protein variant encoded by Rps24c , in brains with Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, and relevant mouse models, using isoform-specific antibodies. These findings establish heterogeneous RP expression as a feature of brain cell types and identify Rps24c /S24-PKE as a novel marker for neuroinflammation and neurodegeneration.

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Collaborators (90)

Stefanie Heilmann-Heimbach

Head of Laboratory, Research Group Leader

University Hospital Bonn

GERMANY
View details

Ruth Frikke-Schmidt

Professor, Chief Physician, MD PhD DMSc

-

DENMARK
View details

Maria Jesús Bullido Gómez-Heras

Researcher

Universidad Autónoma de Madrid

SPAIN
View details

Olga E Titova

Assistant Professor

Uppsala Universitet Medicinska fakulteten

SWEDEN
View details

Bernardino Ghetti

Distinguished Professor

Indiana University School of Medicine

UNITED STATES
View details

Pau Pastor

Institut Català de la Salut

SPAIN
View details

Eloy Rodriguez-Rodríguez

Instituto de Investigación Marqués de Valdecilla

SPAIN
View details

innocenzo rainero

University of Turin

ITALY
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Agustín Ruiz Laza

Director of the Biology Core

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Harro Seelaar

Neurologist

Erasmus MC

NETHERLANDS
View details

Michael Heneka

Director

University of Bonn

GERMANY
View details

Philippe Amouyel

Full Professor

Centre Hospitalier Régional Universitaire de Lille

FRANCE
View details

Jesper Qvist Thomassen

Senior Scientist

Rigshospitalet

DENMARK
View details

Johannes Kornhuber

-

GERMANY
View details

Walker Jackson

Senior lecturer

Linköping University

SWEDEN
View details

Ruth Loos

The Charles Bronfman Professor in Personalized Medicine

Københavns Universitet

DENMARK
View details

Henne Holstege

Professor

KU Leuven

BELGIUM
View details

Marco Spallazzi

Adjunt professor

University of Parma

ITALY
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Benedetta Nacmias

University of Florence

ITALY
View details

Suzanne Schindler

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Lucilla Parnetti

Professor of Neurology

University of Perugia

ITALY
View details

Caroline Jonson

University of California, San Francisco

UNITED STATES
View details

Pieter Jelle Visser

Karolinska Institutet

SWEDEN
View details

Jordi Pérez-Tur

Coordinador Adjunto al Área Global Vida

Agencia Estatal Consejo Superior de Investigaciones Científicas

SPAIN
View details

Patrizia Mecocci

Director

Karolinska Institutet

SWEDEN
View details

Caroline Graff

Professor,MD PhD

Karolinska Institutet

SWEDEN
View details

Henna Martiskainen

University of Eastern Finland

FINLAND
View details

Amy Kit Yu Fu

Research Professor

The Hong Kong University of Science and Technology

HONG KONG
View details

Arvid Rongve

Professor

University of Bergen

NORWAY
View details

Jean-Charles Lambert

Head of research unit

INSERM

FRANCE
View details

Betty Tijms

Senior researcher

VU medisch centrum

NETHERLANDS
View details

Joel Watts

Associate Professor

University of Toronto

CANADA
View details

Simon Laws

Professor

Edith Cowan University

AUSTRALIA
View details

Nancy Yuk-Yu Ip

The Morningside Professor of Life Science

The Hong Kong University of Science and Technology

HONG KONG
View details

Katja Scheffler

Associate Professor

Norwegian University of Science and Technology

NORWAY
View details

Takeshi Ikeuchi

Professor

Brain Research Institute, Niigata University

JAPAN
View details

Jonathan Vogelgsang

Harvard University

UNITED STATES
View details

Ciyang Wang

Washington University in St. Louis

UNITED STATES
View details

Geir Selbaek

Professor

University of Oslo

NORWAY
View details

Timothy Hohman

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Pablo Mir

-

SPAIN
View details

Norbert Scherbaum

Professor for Clinical Addiction Research

University of Duisburg-Essen Faculty of Medizin

GERMANY
View details

Tormod Fladby

Professor ll of Neurology

University of Oslo

NORWAY
View details

Margda Waern

University of Gothenburg

SWEDEN
View details

Gesine Paul

Lund University

SWEDEN
View details

Muhammad Ali

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Bradley Hyman

Professor

Harvard University

UNITED STATES
View details

Andrew Saykin

Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center

Indiana University School of Medicine

UNITED STATES
View details

Srdjan Djurovic

Professor at University of Oslo

University of Oslo

NORWAY
View details

Sami Heikkinen

Research Director

University of Eastern Finland

FINLAND
View details

Najaf Amin

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Wiesje van der Flier

Scientific director

VU medisch centrum

NETHERLANDS
View details

Peter Holmans

Professor of Biostatistics and Genetic Epidemiology

Cardiff University

UNITED KINGDOM
View details

Dag Sehlin

Professor

Uppsala Universitet Medicinska fakulteten

SWEDEN
View details

David M. Holtzman

Washington University School of Medicine

UNITED STATES
View details

Dan Rujescu

Head of Clinical Division of General Psychiatry

Medical University of Vienna

AUSTRIA
View details

Alessio Squassina

Dalhousie University

CANADA
View details

Carole Dufouil

Director of research

INSERM

FRANCE
View details

Virginia M-Y Lee

Professor

University of Pennsylvania

UNITED STATES
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Hilkka Soininen

Kuopio University Hospital

FINLAND
View details

María José Romero Lado

University of Copenhagen

DENMARK
View details

Gael Nicolas

PUPH

University of Rouen

FRANCE
View details

Åsa Mackenzie

Senior Lecturer

Lund University

SWEDEN
View details

Riccardo E Marioni

University of Edinburgh

UNITED KINGDOM
View details

Anssi Lipponen

University of Eastern Finland

FINLAND
View details

Patrick Kehoe

Academic , Gestetner Professor of Translational Dementia Research

University of Bristol

UNITED KINGDOM
View details

Alison Goate

Professor and Chair

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Alfredo Ramirez

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

INGVILD SALTVEDT

Professor

Norwegian University of Science and Technology

NORWAY
View details

Dag Aarsland

Professor and Head of Department

King’s College London

UNITED KINGDOM
View details

Daniela Galimberti

Associate Professor

Università degli Studi di Torino

ITALY
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Ole A. Andreassen

Oslo University Hospital

NORWAY
View details

Lucio Tremolizzo

Associate Professor of Neurology

University of Milano-Bicocca

ITALY
View details

Valentina Escott-Price

Professor

Cardiff University

UNITED KINGDOM
View details

Ville Leinonen

Professor

University of Eastern Finland

FINLAND
View details

Lutz Froelich

Head

Zentralinstitut für Seelische Gesundheit

GERMANY
View details

Rebecca Sims

Senior Research Fellow

Cardiff University

UNITED KINGDOM
View details

Barbara Borroni

Docenti di ruolo di IIa fascia

University of Brescia

ITALY
View details

Lars Bertram

Professor of Genome Analytics

University of Lübeck

GERMANY
View details

Jose Luis Royo

University of Malaga

SPAIN
View details

Mikko Hiltunen

University of Eastern Finland

FINLAND
View details

Cornelia Van Duijn

Professor

University of Oxford

UNITED KINGDOM
View details

Alberto Lleó

Director

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Sterling Johnson

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Menghan Liu

Washington University in St. Louis

UNITED STATES
View details

Tuomas Kilpeläinen

Assistant professor

Københavns Universitet

DENMARK
View details